PMID- 34346560 OWN - NLM STAT- MEDLINE DCOM- 20220303 LR - 20220303 IS - 2045-7634 (Electronic) IS - 2045-7634 (Linking) VI - 10 IP - 17 DP - 2021 Sep TI - Bilateral breast cancer in China: A 10-year single-center retrospective study (2006-2016). PG - 6089-6098 LID - 10.1002/cam4.4141 [doi] AB - Bilateral breast cancer (BBC) is an uncommon subset of breast cancer (BC), and it may present as synchronous bilateral breast cancer (sBBC) or metachronous bilateral breast cancer (mBBC). Through this study, we aimed to evaluate the proportion of BBC in BC and compare the clinicopathological characteristics, treatment, and outcomes of sBBC and mBBC at an academic cancer center in China. Patients with BC consecutively treated between 2006 and 2016 were retrospectively reviewed. Patients with BBC were included. In total, 3924 patients with BC were analyzed and 127 patients with BBC (28 sBBC, 99 mBBC) with a median follow-up of 98 months were identified. The proportion of BBC was 3.2% (0.7%, sBBC; 2.5%, mBBC). The median age at the first diagnosis of mBBC was significantly younger than that at the first diagnosis of sBBC (p = 0.027). Patients diagnosed as having sBBC were more likely to have a positive family history (p = 0.047). The first tumors of mBBC were detected at a significantly earlier tumor stage compared with those of sBBC (p = 0.028). The concordance rates of histopathologic type in the first and second tumors were 60.7% and 58.0% in sBBC and mBBC, respectively. sBBC had a significantly poorer disease-free survival than mBBC did (p = 0.001). BBC is a rare disease affecting the Chinese population. sBBC is associated with a greater prevalence of a family history of breast cancer and poorer prognosis, compared with mBBC. CI - (c) 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. FAU - Jiang, Hanfang AU - Jiang H AUID- ORCID: 0000-0002-3502-7073 AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Zhang, Ruyan AU - Zhang R AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Liu, Xiaoran AU - Liu X AUID- ORCID: 0000-0003-0912-3210 AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Ran, Ran AU - Ran R AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Zhang, Jiayang AU - Zhang J AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Liu, Yaxin AU - Liu Y AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Gui, Xinyu AU - Gui X AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Chen, Yifei AU - Chen Y AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Li, Kun AU - Li K AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Shao, Bin AU - Shao B AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Yan, Ying AU - Yan Y AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Liang, Xu AU - Liang X AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Song, Guohong AU - Song G AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Di, Lijun AU - Di L AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. FAU - Li, Huiping AU - Li H AUID- ORCID: 0000-0002-3331-647X AD - Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China. LA - eng PT - Journal Article DEP - 20210804 PL - United States TA - Cancer Med JT - Cancer medicine JID - 101595310 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Breast Neoplasms/*epidemiology MH - China MH - Female MH - Humans MH - Middle Aged MH - Prognosis MH - Retrospective Studies MH - Time Factors PMC - PMC8419776 OTO - NOTNLM OT - bilateral breast cancer OT - metachronous OT - prognosis OT - proportion OT - synchronous COIS- The authors declare that they have no conflict of interest. EDAT- 2021/08/05 06:00 MHDA- 2022/03/04 06:00 PMCR- 2021/08/04 CRDT- 2021/08/04 09:00 PHST- 2021/04/09 00:00 [revised] PHST- 2021/02/11 00:00 [received] PHST- 2021/07/02 00:00 [accepted] PHST- 2021/08/05 06:00 [pubmed] PHST- 2022/03/04 06:00 [medline] PHST- 2021/08/04 09:00 [entrez] PHST- 2021/08/04 00:00 [pmc-release] AID - CAM44141 [pii] AID - 10.1002/cam4.4141 [doi] PST - ppublish SO - Cancer Med. 2021 Sep;10(17):6089-6098. doi: 10.1002/cam4.4141. Epub 2021 Aug 4.